Cargando…

CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease

Alzheimer's disease (AD) is characterized by neuronal atrophy caused by soluble amyloid β protein (Aβ) peptide “oligomers” and a microglial-mediated inflammatory response elicited by extensive amyloid deposition in the brain. We show that CNI-1493, a tetravalent guanylhydrazone with established...

Descripción completa

Detalles Bibliográficos
Autores principales: Bacher, Michael, Dodel, Richard, Aljabari, Bayan, Keyvani, Kathy, Marambaud, Philippe, Kayed, Rakez, Glabe, Charles, Goertz, Nicole, Hoppmann, Anne, Sachser, Norbert, Klotsche, Jens, Schnell, Susanne, Lewejohann, Lars, Al-Abed, Yousef
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442637/
https://www.ncbi.nlm.nih.gov/pubmed/18573905
http://dx.doi.org/10.1084/jem.20060467
_version_ 1782156718422097920
author Bacher, Michael
Dodel, Richard
Aljabari, Bayan
Keyvani, Kathy
Marambaud, Philippe
Kayed, Rakez
Glabe, Charles
Goertz, Nicole
Hoppmann, Anne
Sachser, Norbert
Klotsche, Jens
Schnell, Susanne
Lewejohann, Lars
Al-Abed, Yousef
author_facet Bacher, Michael
Dodel, Richard
Aljabari, Bayan
Keyvani, Kathy
Marambaud, Philippe
Kayed, Rakez
Glabe, Charles
Goertz, Nicole
Hoppmann, Anne
Sachser, Norbert
Klotsche, Jens
Schnell, Susanne
Lewejohann, Lars
Al-Abed, Yousef
author_sort Bacher, Michael
collection PubMed
description Alzheimer's disease (AD) is characterized by neuronal atrophy caused by soluble amyloid β protein (Aβ) peptide “oligomers” and a microglial-mediated inflammatory response elicited by extensive amyloid deposition in the brain. We show that CNI-1493, a tetravalent guanylhydrazone with established antiinflammatory properties, interferes with Aβ assembly and protects neuronal cells from the toxic effect of soluble Aβ oligomers. Administration of CNI-1493 to TgCRND8 mice overexpressing human amyloid precursor protein (APP) for a treatment period of 8 wk significantly reduced Aβ deposition. CNI-1493 treatment resulted in 70% reduction of amyloid plaque area in the cortex and 87% reduction in the hippocampus of these animals. Administration of CNI-1493 significantly improved memory performance in a cognition task compared with vehicle-treated mice. In vitro analysis of CNI-1493 on APP processing in an APP-overexpressing cell line revealed a significant dose-dependent decrease of total Aβ accumulation. This study indicates that the antiinflammatory agent CNI-1493 can ameliorate the pathophysiology and cognitive defects in a murine model of AD.
format Text
id pubmed-2442637
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-24426372009-01-07 CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease Bacher, Michael Dodel, Richard Aljabari, Bayan Keyvani, Kathy Marambaud, Philippe Kayed, Rakez Glabe, Charles Goertz, Nicole Hoppmann, Anne Sachser, Norbert Klotsche, Jens Schnell, Susanne Lewejohann, Lars Al-Abed, Yousef J Exp Med Brief Definitive Reports Alzheimer's disease (AD) is characterized by neuronal atrophy caused by soluble amyloid β protein (Aβ) peptide “oligomers” and a microglial-mediated inflammatory response elicited by extensive amyloid deposition in the brain. We show that CNI-1493, a tetravalent guanylhydrazone with established antiinflammatory properties, interferes with Aβ assembly and protects neuronal cells from the toxic effect of soluble Aβ oligomers. Administration of CNI-1493 to TgCRND8 mice overexpressing human amyloid precursor protein (APP) for a treatment period of 8 wk significantly reduced Aβ deposition. CNI-1493 treatment resulted in 70% reduction of amyloid plaque area in the cortex and 87% reduction in the hippocampus of these animals. Administration of CNI-1493 significantly improved memory performance in a cognition task compared with vehicle-treated mice. In vitro analysis of CNI-1493 on APP processing in an APP-overexpressing cell line revealed a significant dose-dependent decrease of total Aβ accumulation. This study indicates that the antiinflammatory agent CNI-1493 can ameliorate the pathophysiology and cognitive defects in a murine model of AD. The Rockefeller University Press 2008-07-07 /pmc/articles/PMC2442637/ /pubmed/18573905 http://dx.doi.org/10.1084/jem.20060467 Text en © 2008 Bacher et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Brief Definitive Reports
Bacher, Michael
Dodel, Richard
Aljabari, Bayan
Keyvani, Kathy
Marambaud, Philippe
Kayed, Rakez
Glabe, Charles
Goertz, Nicole
Hoppmann, Anne
Sachser, Norbert
Klotsche, Jens
Schnell, Susanne
Lewejohann, Lars
Al-Abed, Yousef
CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease
title CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease
title_full CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease
title_fullStr CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease
title_full_unstemmed CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease
title_short CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease
title_sort cni-1493 inhibits aβ production, plaque formation, and cognitive deterioration in an animal model of alzheimer's disease
topic Brief Definitive Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442637/
https://www.ncbi.nlm.nih.gov/pubmed/18573905
http://dx.doi.org/10.1084/jem.20060467
work_keys_str_mv AT bachermichael cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT dodelrichard cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT aljabaribayan cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT keyvanikathy cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT marambaudphilippe cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT kayedrakez cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT glabecharles cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT goertznicole cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT hoppmannanne cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT sachsernorbert cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT klotschejens cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT schnellsusanne cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT lewejohannlars cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease
AT alabedyousef cni1493inhibitsabproductionplaqueformationandcognitivedeteriorationinananimalmodelofalzheimersdisease